TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35461639

Group type: EXPERIMENTAL
Intervention: V block
Number of subjects: 140

Group type: COMPARATOR
Intervention: H block
Number of subjects: 140
Study: 32782323

Group type: EXPERIMENTAL
Intervention: Umbilical cord milking (UCM)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Early cord clamping (ECC)
Number of subjects: 73
Study: 36457653

Group type: EXPERIMENTAL
Intervention: Citrus aurantium essential oil (2 drops, twice a day, for four consecutive days a week, for four weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 32791810

Group type: EXPERIMENTAL
Intervention: Cipterbin (4 mg/kg loading dose and 2 mg/kg maintenance dose each week, IV) combined with vinorelbine (25 mg/m(2) on days 1,8 and 15 of each 28 days, IV)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Vinorelbine (25 mg/m(2) on days 1,8 and 15 of each 28 days, IV)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Cipterbin combined with vinorelbine
Number of subjects: 315

Group type: COMPARATOR
Intervention: Vinorelbine
Number of subjects: 315
Study: 36222438

Group type: EXPERIMENTAL
Intervention: ELOM-080 (4 × 1 capsule per day)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: ELOM-080
Number of subjects: 463

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 463
Study: 33745481

Group type: EXPERIMENTAL
Intervention: Goal Management Training (GMT) in eight sessions
Number of subjects: 25

Group type: COMPARATOR
Intervention: Active control group (CG) with psychoeducation sessions
Number of subjects: 25
Study: 33047511

Group type: EXPERIMENTAL
Intervention: 22-gauge atraumatic needle (Sprotte, 22GS)
Number of subjects: 151

Group type: COMPARATOR
Intervention: 22-gauge traumatic needle (Quincke, 22GQ)
Number of subjects: 151
Study: 35411076

Group type: EXPERIMENTAL
Intervention: AAV8‐VRC07 (5 × 10^10, 5 × 10^11, and 2.5 × 10^12 vector genomes per kilogram by intramuscular injection)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: AAV8‐VRC07
Number of subjects: 8
Study: 32673048

Group type: EXPERIMENTAL
Intervention: Alcohol (target blood alcohol concentration of .08 g%)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 448
Study: 32416434

Group type: EXPERIMENTAL
Intervention: Shoulder brace with forced tension and diagonal configuration
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Shoulder brace (general)
Number of subjects: 24
Study: 34668982

Group type: EXPERIMENTAL
Intervention: Carfilzomib (36 mg/m2) administered on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle
Number of subjects: 15
Study: 34913431

Group type: EXPERIMENTAL
Intervention: Video instruction at home
Number of subjects: 120

Group type: COMPARATOR
Intervention: Classic instruction by a nurse
Number of subjects: 120
Study: 34742613

Group type: EXPERIMENTAL
Intervention: Self-reported leisure time physical activity (some physical activity)
Number of subjects: 761
Study: 34221933

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Esmolol
Number of subjects: 29
Study: 35769038

Group type: EXPERIMENTAL
Intervention: ACP+ intervention (multicomponent training and support for nursing home staff over 8 months)
Number of subjects: 694

Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 694
Study: 33714077

Group type: EXPERIMENTAL
Intervention: Supported employment intervention for mood or anxiety disorders
Number of subjects: 261
Study: 32657704

Group type: EXPERIMENTAL
Intervention: Predischarge transcutaneous bilirubin (TcB) screening
Number of subjects: 1858

Group type: COMPARATOR
Intervention: Visual assessment (control)
Number of subjects: 1858
Study: 33733720

Group type: EXPERIMENTAL
Intervention: Perineural corticosteroid injection (Methylprednisolone acetate 40 mg and 1 mL of 1% trimecaine hydrochloride injected next to the median nerve)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Peritendinous corticosteroid injection (Methylprednisolone acetate 40 mg and 1 mL of 1% trimecaine hydrochloride injected among flexor tendons away from the nerve)
Number of subjects: 46
Study: 32910476

Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 652

Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Overall trial population
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Interaction between treatment arms
Number of subjects: 652
Study: 35420624

Group type: EXPERIMENTAL
Intervention: Educational video
Number of subjects: 138

Group type: COMPARATOR
Intervention: Verbal instructions (Control)
Number of subjects: 138
Study: 33223073

Group type: EXPERIMENTAL
Intervention: Surgeons performing CEA with >10 cases/year
Number of subjects: 7331

Group type: EXPERIMENTAL
Intervention: Surgeons performing CEA with >25 cases/year
Number of subjects: 7331

Group type: EXPERIMENTAL
Intervention: Vascular surgeons performing >10 CEA
Number of subjects: 7331

Group type: COMPARATOR
Intervention: Annual surgeon volume thresholds from RCTs
Number of subjects: 7331
Study: 32404013

Group type: EXPERIMENTAL
Intervention: Promoter variants with mutations in binding region
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Promoter variants with mutations in melting region
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Promoter variants with mutations in both regions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Substitution of -2A to -2T
Number of subjects: 0
Study: 35260570

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Combination of a RAC1/RAC3 dual-target inhibitor and cetuximab
Number of subjects: 110
Study: 33305109

Group type: EXPERIMENTAL
Intervention: Etelcalcetide + active vitamin D (group E+D)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Etelcalcetide + oral calcium preparation (group E+Ca)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 124
Study: 35367787

Group type: EXPERIMENTAL
Intervention: Metronomic adjuvant chemotherapy (MAC) consisting of weekly oral methotrexate (15 mg/m²) and celecoxib (200 mg orally twice daily) for 6 months
Number of subjects: 105

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 105
Study: 33984219

Group type: EXPERIMENTAL
Intervention: Adductor canal block performed before tourniquet inflation (PreT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adductor canal block performed after tourniquet inflation (PostT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adductor canal block performed at the end of surgery after deflation of the tourniquet (PO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: All groups (PreT, PostT, PO)
Number of subjects: 0
Study: 32485550

Group type: EXPERIMENTAL
Intervention: Psychological and physical IPV perpetration and victimization
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conflict behaviors
Number of subjects: 30
Study: 34461042

Group type: EXPERIMENTAL
Intervention: Haemodynamic-guided management based on pulmonary artery pressure
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Haemodynamic-guided management (pre-COVID-19 analysis)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Usual care control group (pre-COVID-19 analysis)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Haemodynamic-guided management during COVID-19
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Usual care control group during COVID-19
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Overall study analysis
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Pre-COVID-19 impact analysis
Number of subjects: 1000
Study: 33849856

Group type: EXPERIMENTAL
Intervention: Postoperative dexmedetomidine sedation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard institutional sedation protocols
Number of subjects: 0
Study: 32222134

Group type: EXPERIMENTAL
Intervention: Vericiguat (10 mg once daily)
Number of subjects: 5050

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5050
Study: 35415940

Group type: EXPERIMENTAL
Intervention: M‐MIST alone
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: M‐MIST+EMD
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: M‐MIST+EMD+BMDX
Number of subjects: 45
Study: 35977769

Group type: EXPERIMENTAL
Intervention: Diazoxide 5 mg/kg orally loading dose, then 1.5 mg/kg every 12 hours maintenance dose, titrated to target BGC 2.6‐5.4 mmol/L
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo, equal volume to diazoxide
Number of subjects: 100
Study: 34342893

Group type: EXPERIMENTAL
Intervention: Gel nail polish application
Number of subjects: 40

Group type: COMPARATOR
Intervention: No polish (control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nail length (2 to <3-mm and ≥3-mm)
Number of subjects: 40
Study: 32361696

Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 33932093

Group type: EXPERIMENTAL
Intervention: Single oral dose of apremilast at 20, 30, or 40 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Multiple oral doses of apremilast at 30 mg b.i.d. for 14 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 28
Study: 34334736

Group type: EXPERIMENTAL
Intervention: Web-only protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mail (postal) only protocol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined protocol (web with postal mail follow-up)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Respondents without email addresses
Number of subjects: 0
Study: 35707932

Group type: EXPERIMENTAL
Intervention: Short stitch technique (5 to 8 mm every 5 mm, USP 2-0, single thread HR 26 mm needle)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Long stitch technique (10 mm every 10 mm, USP 1, double loop, HR 48 mm needle)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Short stitch technique
Number of subjects: 425
Study: 33407130

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway-Supreme (LMA-S)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 80
Study: 33443290

Group type: EXPERIMENTAL
Intervention: Elastic bandaging
Number of subjects: 94

Group type: COMPARATOR
Intervention: Plaster casting
Number of subjects: 94
Study: 32876689

Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone (n=76)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo (n=73)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 34400397

Group type: EXPERIMENTAL
Intervention: Multi-mode education program for pharmacists (five evidence-based online modules and skills review)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Multi-mode education program for pharmacists
Number of subjects: 97
Study: 34509954

Group type: EXPERIMENTAL
Intervention: Intermittent pazopanib (IP)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Continuous pazopanib (CP)
Number of subjects: 168
Study: 32548811

Group type: EXPERIMENTAL
Intervention: ALBI grade-based prognostic nomogram
Number of subjects: 1051

Group type: EXPERIMENTAL
Intervention: Presence of ascites, ALBI grade 2–3, serum ɑ-fetoprotein level ≥ 400 ng/mL, total tumor volume ≥ 396 cm3, presence of vascular invasion, poor performance status
Number of subjects: 1051
Study: 35304018

Group type: EXPERIMENTAL
Intervention: Education using a rhinoplasty training guide prior to surgery
Number of subjects: 79

Group type: COMPARATOR
Intervention: Routine plastic surgery procedures (Control)
Number of subjects: 79
Study: 33580803

Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham dry needling
Number of subjects: 46
Study: 34263472

Group type: EXPERIMENTAL
Intervention: Edasalonexent softgel capsules (100 mg or 250 mg)
Number of subjects: 181
Study: 32969699

Group type: EXPERIMENTAL
Intervention: Vigorous intensity exercise
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Short duration exercise
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Long duration exercise
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Overall exercise training
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Baseline affective response scores
Number of subjects: 201
Study: 36103415

Group type: EXPERIMENTAL
Intervention: Aggressive fluid resuscitation (20 ml/kg bolus, followed by 3 ml/kg/hour)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Moderate fluid resuscitation (10 ml/kg bolus for hypovolemia or no bolus for normovolemia, followed by 1.5 ml/kg/hour)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Aggressive fluid resuscitation
Number of subjects: 249

Group type: COMPARATOR
Intervention: Moderate fluid resuscitation
Number of subjects: 249
Study: 32940732

Group type: EXPERIMENTAL
Intervention: Ultra-congruent (UC) inserts
Number of subjects: 66

Group type: COMPARATOR
Intervention: Posterior stabilized (PS) inserts
Number of subjects: 66
Study: 32046767

Group type: EXPERIMENTAL
Intervention: Anticipatory Care Planning (ACP) intervention delivered by specially trained registered nurses in a primary care setting
Number of subjects: 0
Study: 35751772

Group type: EXPERIMENTAL
Intervention: High dose tranexamic acid (TXA): 50 mg/kg, 5 mg/kg/hr
Number of subjects: 62
Study: 34225395

Group type: EXPERIMENTAL
Intervention: Case-based learning (CBL) teaching program
Number of subjects: 107

Group type: COMPARATOR
Intervention: Traditional teacher-centered method
Number of subjects: 107
Study: 35123664

Group type: EXPERIMENTAL
Intervention: Probiotic and peanut oral immunotherapy (PPOIT)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy (OIT)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: PPOIT
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: OIT
Number of subjects: 201
Study: 36126603

Group type: EXPERIMENTAL
Intervention: Personalized swallowing rehabilitation twice a day for 10 days
Number of subjects: 68

Group type: COMPARATOR
Intervention: Routine nursing and health education
Number of subjects: 68
Study: 34615696

Group type: EXPERIMENTAL
Intervention: Fourth R intervention (classroom-based curriculum, 21 lessons on injury prevention, substance use, and growth and development)
Number of subjects: 1237

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1237

Group type: EXPERIMENTAL
Intervention: Fourth R intervention
Number of subjects: 1237

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1237
Study: 33350756

Group type: EXPERIMENTAL
Intervention: Bone graft intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard postoperative protocols
Number of subjects: 0
Study: 36078233

Group type: EXPERIMENTAL
Intervention: β‐endorphin levels before chemotherapy
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: β‐endorphin levels after chemotherapy
Number of subjects: 139

Group type: COMPARATOR
Intervention: β‐endorphin levels
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Serotonin levels before chemotherapy
Number of subjects: 139
Study: 33331038

Group type: EXPERIMENTAL
Intervention: Parental participation in the care of hospitalized children
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no parental participation)
Number of subjects: 0
Study: 34645654

Group type: EXPERIMENTAL
Intervention: SPACE intervention (automated search, pharmacist outreach, patient invitation for medication review)
Number of subjects: 21877

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21877

Group type: EXPERIMENTAL
Intervention: SPACE intervention
Number of subjects: 21877
Study: 33306229

Group type: EXPERIMENTAL
Intervention: EVR + TAC
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: EVR + CyA
Number of subjects: 90

Group type: COMPARATOR
Intervention: MPA + TAC
Number of subjects: 90
Study: 32036193

Group type: EXPERIMENTAL
Intervention: STan+CTG
Number of subjects: 32

Group type: COMPARATOR
Intervention: CTG alone
Number of subjects: 32
Study: 35689147

Group type: EXPERIMENTAL
Intervention: Current relationship with male partner living with HIV
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: No current relationship with only female past partners
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: No current relationship
Number of subjects: 718
Study: 32602588

Group type: EXPERIMENTAL
Intervention: Home-care nursing intervention (three home visits by nurses in 1 month after hospital discharge)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (relying on the service network)
Number of subjects: 48
Study: 32557260

Group type: EXPERIMENTAL
Intervention: Zinc acetate hydrate (ZAH; zinc, 50 mg/day)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Polaprezinc (PPZ; zinc, 34 mg/day)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Pre-dialysis SCre level ≥ 10.0 mg/dL
Number of subjects: 91
Study: 34470119

Group type: EXPERIMENTAL
Intervention: Reminder system (laboratory requisition and telephone reminder)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Reminder system (public insurance)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Routine care (public insurance)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Completed test
Number of subjects: 75
Study: 33351892

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 627

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 627
Study: 32729120

Group type: EXPERIMENTAL
Intervention: 15 mg CBD
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 300 mg CBD
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1,500 mg CBD
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 35697050

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 recombinant protein vaccine (high dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34203025

Group type: EXPERIMENTAL
Intervention: CDSS group (n = 27)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (n = 28)
Number of subjects: 55
Study: 34332895

Group type: EXPERIMENTAL
Intervention: Topical lotilaner ophthalmic solution, 0.25%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 60
Study: 32281592

Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PR) intervention in the dorsal root ganglion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conservative treatment (control group)
Number of subjects: 50
Study: 34668065

Group type: EXPERIMENTAL
Intervention: Topical application of Otosporin®
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo application
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (Otosporin® and placebo)
Number of subjects: 20
Study: 34615514

Group type: EXPERIMENTAL
Intervention: Breath analysis using gas chromatography coupled with ion mobility spectrometry and machine learning in OSCC patients
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group of healthy subjects
Number of subjects: 105
Study: 32799781

Group type: EXPERIMENTAL
Intervention: Bird Tales program
Number of subjects: 0
Study: 32789678

Group type: EXPERIMENTAL
Intervention: Multi-proteomic approach (including troponin and BNP)
Number of subjects: 5131

Group type: EXPERIMENTAL
Intervention: Multi-proteomic biomarkers (troponin, BNP, TRAILR2, Gal-9, FGF23, AMBP)
Number of subjects: 5131

Group type: EXPERIMENTAL
Intervention: BNP and Gal-9
Number of subjects: 5131

Group type: EXPERIMENTAL
Intervention: Troponin, FGF23, AMBP
Number of subjects: 5131

Group type: EXPERIMENTAL
Intervention: Troponin
Number of subjects: 5131

Group type: EXPERIMENTAL
Intervention: Multi-proteomics
Number of subjects: 5131

Group type: EXPERIMENTAL
Intervention: Final biomarker selection added to clinical model
Number of subjects: 5131
Study: 32712884

Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus daclatasvir for 3 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paritaprevir, ombitasvir and ritonavir plus ribavirin for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: IL28B genotypes correlation with sustained virologic response
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline fibroscan scores
Number of subjects: 0
Study: 35469110

Group type: EXPERIMENTAL
Intervention: Active suctioning
Number of subjects: 60

Group type: COMPARATOR
Intervention: Simple compression
Number of subjects: 60
Study: 33970012

Group type: EXPERIMENTAL
Intervention: Supportive-educative nursing intervention programme
Number of subjects: 168
Study: 35916680

Group type: EXPERIMENTAL
Intervention: CEUS-guided biopsy (CEUS-GB)
Number of subjects: 2056

Group type: COMPARATOR
Intervention: US-guided biopsy (US-GB)
Number of subjects: 2056
Study: 33372533

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiovascular disease (CVD)
Number of subjects: 0
Study: 35122085

Group type: EXPERIMENTAL
Intervention: Aspirin use >60 days/year
Number of subjects: 14315

Group type: COMPARATOR
Intervention: Aspirin use ≤60 days/year
Number of subjects: 14315

Group type: COMPARATOR
Intervention: Not walking regularly (reference group)
Number of subjects: 14315

Group type: COMPARATOR
Intervention: Walking <2 mph
Number of subjects: 14315

Group type: COMPARATOR
Intervention: Walking ≥2-2.9 mph
Number of subjects: 14315

Group type: COMPARATOR
Intervention: Walking ≥3 mph
Number of subjects: 14315
Study: 32220414

Group type: EXPERIMENTAL
Intervention: Buprenorphine initiation (8 mg sublingual buprenorphine or 8-2 mg sublingual buprenorphine/naloxone)
Number of subjects: 6523

Group type: COMPARATOR
Intervention: Screening for substance misuse
Number of subjects: 6523
Study: 35085874

Group type: EXPERIMENTAL
Intervention: early adenotonsillectomy (eAT)
Number of subjects: 397

Group type: COMPARATOR
Intervention: watchful waiting with supportive care (WWSC)
Number of subjects: 397
Study: 32926851

Group type: EXPERIMENTAL
Intervention: Walking training on a walking track with different surfaces (WTDS) (n=28) for 30 min/d, 5 d/wk over 4 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Overground walking training (n=26) for 30 min/d, 5 d/wk over 4 weeks
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Walking training on a walking track with different surfaces (WTDS) (n=28)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Overground walking training (n=26)
Number of subjects: 54